MannKind Corporation (MNKD): MannKind: A Breakout Biotechnology Bet

26-11-2013 Seeking AlphaComments (0)


In my previous reports on MannKind (MNKD), I have discussed the value of the breakthrough diabetics' treatment of MannKind. Its lead diabetes product candidate Afrezza is in the late stage clinical trials and awaiting approval from the FDA. The company ...

Read more on Seeking Alpha

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top